NIH

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

Dotmatics' LabArchives ELN Solution Achieves "In Process" Designation from FedRAMP, Sponsored by National Institutes of Health

Retrieved on: 
Thursday, April 4, 2024
Dotmatics, NCI, Government, Organization, Schedule, NCATS, Documentation, Environment, Federation, Research, National Cancer Institute, News, Management, ELN, LabArchives, NIH, NIST, Risk assessment, National archives, Inventory, Confidentiality, FedRAMP, Bangladesh Technical Education Board, Calendar, ISO, Data management, Medical device

BOSTON, April 4, 2024 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced that its LabArchives for Government solution has achieved the "In-Process" designation granted by the Federal Risk and Authorization Management Program (FedRAMP®). LabArchives' FedRAMP application is sponsored by the National Cancer Institute of the National Institutes of Health (NIH). LabArchives lets organizations securely organize, search, and share data in a powerful electronic lab notebook (ELN) that supports scientific research and breakthroughs. The news is a critical milestone on the path to attaining FedRAMP authorization. LabArchives for Government is now listed on the FedRAMP Marketplace and will operate as a trusted partner to federal agencies upon authorization.

Key Points: 
  • LabArchives' FedRAMP application is sponsored by the National Cancer Institute of the National Institutes of Health (NIH).
  • LabArchives lets organizations securely organize, search, and share data in a powerful electronic lab notebook (ELN) that supports scientific research and breakthroughs.
  • LabArchives for Government is now listed on the FedRAMP Marketplace and will operate as a trusted partner to federal agencies upon authorization.
  • FedRAMP is the U.S. government program that provides a safe, standardized approach to security and risk assessment for cloud technologies.

Rady Children's Appoints Praveen Raju, MD, PhD, as the Nathan Gordon Chair and Medical Director of Neuro-Oncology Program

Retrieved on: 
Tuesday, April 2, 2024
Research, Diagnosis, Boston Children's Hospital, Brain, Health, Growth, Neurology, MSTP, Memory, Genetics, SAN, Patient, UC, Cancer, Medulloblastoma, Child, University, Neurosurgery, Doctor of Philosophy, Neuro, MD, Molecular biology, NIH, Laboratory, Pediatric neurosurgery, Neoplasm, Infant, Nathan Gordon, Hospital, Spinal cord, Pediatrics, Neuro-Oncology (journal), Medical director, Genetic distance, Nursing

At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.

Key Points: 
  • At Rady Children's, Dr. Raju has also been named the Nathan Gordon Chair in Neuro-Oncology, established in 2021 to honor the memory of Nathan Gordon, who was diagnosed with a rare tumor in his spinal cord when he was just 15 months old.
  • As part of Rady Children's nationally recognized care team, Dr. Raju will spearhead the growth of the Neuro-Oncology Program and advance research efforts on pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise, Dr. Raju aims to address different forms of pediatric brain and spinal tumors.
  • By incorporating subspecialty expertise into the Neuro-Oncology Program, Dr. Raju aims to address the different forms and distinct molecular subtypes of pediatric brain and spinal tumors.

April is National Stress Awareness Month and author, Steven M. Stroum, Hopes his Business Memoir Helps People Learn How to Manage Stress and Become More Fulfilled

Retrieved on: 
Tuesday, April 2, 2024
Well, Depression, Personality, Tears, Personal, Betrayal, American Psychological Association, News, Entrepreneurship, Small business, NIH, Happiness, CDC, Bangladesh Technical Education Board, Health, Advertising, MHA, Nursing

FRAMINGHAM, Mass., April 2, 2024 /PRNewswire-PRWeb/ -- Prior to becoming an entrepreneur I had several jobs, worked for other people and through acts of my own as well as various supervisors, my life was stressful. Since my stress revolved around work, I wanted to be certain that I was in the right field and doing the right kind of work. So, I sought vocational counseling and that's where I became aware of The Strong Interest Inventory assessment which helps individuals identify their work personality by exploring their interests in six broad areas: realistic, artistic, investigative, social, enterprising, and conventional.

Key Points: 
  • According to the National Institutes of Health, April is recognized as National Stress Awareness Month to bring attention to the negative impact of stress.
  • Knowing how to manage stress can improve mental and physical well-being as well as minimize exacerbation of health-related issues.
  • The Mental Health American (MHA) provides some tips on how to reduce your stress by utilizing a Stress Screener.
  • For me, The Strong Interest Inventory assessment validated that I was doing the right thing, but I was in the wrong field.

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Prevent Blindness Provides Free Resources as Part of April's Women's Eye Health and Safety Month to Educate Women on Necessary Steps to Help Save Sight

Retrieved on: 
Wednesday, March 27, 2024
Orbis, IOP, Pigment, Glaucoma, Le Bonheur Children's Hospital, Social media, Pressure, Visual impairment, Contact, Paratriathlon, Intraocular pressure, AAO, Policy, Orbis International, Hormone, Diabetes, Risk, Mental health, Delta Gamma, NIH, Eyelid, Prevalence, Eye, Associate, Safety, Cataract, Menopause, University, Pregnancy, Hospital, Melasma, Public health, Lactation, Puberty, American Academy, Lens, Telecanthus, Eye disease, Graves' ophthalmopathy, Bangladesh Technical Education Board, Dry eye syndrome, Pediatrics, Birth control

CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month. According to Orbis International, globally there are 112 million more women than men living with vision loss, including blindness. Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.

Key Points: 
  • CHICAGO, March 27, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, has declared April as Women's Eye Health and Safety Month.
  • Prevent Blindness is offering free resources, including fact sheets, shareable social media graphics, educational videos and web pages, on a range of eye health issues that predominantly affect women.
  • Women have a higher prevalence of age-related macular degeneration, cataract, dry eye, glaucoma, refractive error and thyroid eye disease.
  • For more information on women's eye health topics, including fact sheets on eye diseases and eye safety, please visit PreventBlindness.org.

CCRM FERTILITY WELCOMES REGIONAL DIRECTOR OF CLINICAL REPRODUCTIVE GENETICS, DR. JASMINE ALY, TO JERSEY CITY TEAM

Retrieved on: 
Wednesday, March 27, 2024
ART, WRNMMC, Obstetrics, PCOS, Gynaecology, Obesity, Polycystic disease, Reproductive Sciences, Science, NHGRI, Genetic distance, FACOG, Genetics, COVID-19, Patient, Empathy, Medical genetics, Cooper University Hospital, Research, African Americans, USUHS, Fibroid, Reproduction, Assisted reproductive technology, IRMS, NIH, Polycystic ovary syndrome, Outline of health sciences, Reproductive endocrinology and infertility, Publication, Fertility, REI, Birth control

JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey. Dr. Aly holds the rare distinction of being a triple-specialized physician as an Obstetrician-Gynecologist, Reproductive Endocrinologist, and Medical Geneticist.

Key Points: 
  • JERSEY CITY, N.J., March 27, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today that Jasmine Aly, MD, FACOG, will be joining  CCRM | IRMS in New Jersey.
  • As Regional Director of Clinical Reproductive Genetics, Dr. Aly will bring her expertise to the CCRM Fertility team and aims to leverage her comprehensive fellowship training in genetics to further advance the field and better serve patients.
  • As an esteemed reproductive endocrinologist, she will utilize cutting-edge  technology and innovative scientific techniques to ensure patient success rates continue to rise.
  • "Dr. Aly's expertise in genetics is an invaluable attribute that will redefine care at CCRM | IRMS," notes CCRM Fertility CEO, Bob LaGalia.

Research Team Progresses to Final Phase in NIH Competition, Pioneering Autonomic Neuromodulation to Expand Applications for Spinal Stimulation

Retrieved on: 
Thursday, March 21, 2024
Kessler Institute for Rehabilitation, Research, Blood pressure, Reward, Health, TIM, Applied Physics Laboratory, Reynolds Center, Johns Hopkins, SPARC, Learning, Caregiver, News, Rehabilitation, University, Doctor of Philosophy, MD, Quality of life, NIH, Peripheral, Kessler Foundation, Competition, Tetraplegia, Autonomic nervous system, Mobility, Safety, University of Louisville, Neurostimulation, Self-management, Dysautonomia, Bangladesh Technical Education Board, Select Medical, Common Fund for Commodities, Pharmaceutical industry

EAST HANOVER, N.J., March 21, 2024 /PRNewswire/ -- Marking significant progress towards improving the lives of individuals with spinal cord injuries, Kessler Foundation, University of Louisville, and John Hopkins Applied Physics Laboratory (with the support of Medtronic) have collaboratively won the $1,000,000 prize for Phase 2 of the Neuromod Prize for their project titled, "Neuromodulation of the lumbosacral spinal cord for improvement of autonomic function after spinal cord injury." With this win, the team advances to compete for the Phase 3 prize pool of $5 million.

Key Points: 
  • With this win, the team advances to compete for the Phase 3 prize pool of $5 million.
  • Phase 1 called for innovative therapy concepts and development plans, leading to Phase 2's proof-of-concept studies by the eight selected teams.
  • On February 27, 2024, the NIH announced the four Phase 2 victors, marking a breakthrough moment in neuromodulation research.
  • "Most importantly, what we are learning and sharing about neuromodulation through this Competition will influence new approaches to treating other types of disabling autonomic dysfunction."

Women's Health Awareness 2024 Marks 10-year Milestone of Transforming Communities by Enhancing Women's Health

Retrieved on: 
Wednesday, March 20, 2024
Theta, Research, Mindfulness, Health, Hispanic, Conference, Latinx, NIEHS, Delta Sigma, Diabetes, Internet access, Mental, Public, Human, Cancer, NIH, Woman, Community engagement, Disability, Multimedia, Hillside School, WHA, Nursing

RALEIGH DURHAM, N.C., March 20, 2024 /PRNewswire/ -- The Women's Health Awareness (WHA) 2024 Conference marks a decade of enhancing the health of women and communities of color in North Carolina. The free annual event offers health screening, services and environmental health education. The annual event will be held Saturday, April 13, from 8:00 a.m. to 5:00 p.m. Those who pre-register before March 25 will be provided with a complimentary lunch.

Key Points: 
  • RALEIGH DURHAM, N.C., March 20, 2024 /PRNewswire/ -- The Women's Health Awareness (WHA) 2024 Conference marks a decade of enhancing the health of women and communities of color in North Carolina.
  • The free annual event offers health screening, services and environmental health education.
  • Health experts will present up-to-date information on topics of interest to women from the conference location at Hillside High School in Durham, North Carolina.
  • Sessions span environmental health, environmental health justice, and behavioral health.

Biofactura, Inc. Expands presence at Riverside Tech Park in Frederick, Maryland to 17,520 Square Feet

Retrieved on: 
Wednesday, March 20, 2024
Baltimore/Washington International Airport, Quality control, Smallpox, History, National Cancer Institute, Investment, OED, Research, Statistics, NCI, Frederick Municipal Airport, Congestion, Biotechnology, George Washington University, NIH, Workforce, Economic development, Dulles International Airport, Development, Communication, Georgetown University, Cancer, University, Lease, Growth, Johns Hopkins University, Multimedia

FREDERICK, Md., March 20, 2024 /PRNewswire-PRWeb/ -- BioFactura, Inc. has signed a lease with St. John Properties, Inc. for 12,000 square feet of space at Riverside Tech Park, a 70-acre business community located in Frederick, Maryland. The biotechnology firm has occupied 5,520 square feet of space at 8435 Progress Drive in Riverside Technology Park since 2015 and this new requirement expands the company's presence to 17,520 square feet of space within the building. Danny Foit, Leasing Representative for St. John Properties represented the landlord.

Key Points: 
  • The biotechnology firm has occupied 5,520 square feet of space at 8435 Progress Drive in Riverside Technology Park since 2015 and this new requirement expands the company's presence to 17,520 square feet of space within the building.
  • "Riverside Tech Park is a well-designed and strategically-located business community," Dr. Hausfeld added.
  • BioFactura's product has the potential to prepare, augment current countermeasures and guard against a possible smallpox breakout on a global scale.
  • BioFactura relocated in 2015 with the initial 5,520 square foot facility at Riverside Tech Park.